Browse > Article
http://dx.doi.org/10.13160/ricns.2016.9.1.23

Molecular Docking Study of Novel Anti-Hepatitis B Virus Agents Isolated from Talaromyces Species  

Babu, Sathya (Department of Bioinformatics, School of Bioengineering, SRM University)
Publication Information
Journal of Integrative Natural Science / v.9, no.1, 2016 , pp. 23-27 More about this Journal
Abstract
Hepatitis B virus is the leading source of liver disorders and is a global health problem and needs advancements in its treatment against increasing problems. Recently five vanitaracin derivatives were isolated from the fungus Talaromyces species which have anti-Hepatitis B virus activity. Hence, in the present study, molecular docking was carried out with five vanitaracin derivatives isolated from Talaromyces species and three known inhibitors.The objective of this work is to study the interaction of newly isolated compounds and compare its interaction with known inhibitors. The docking results revealed that vanitaracin derivatives have good interactions and has better docking score with the Hepatitis B virus and suggest SER2, SER4 and ASP30 are important residues involved in interaction with the inhibitors. These result authenticates vanitaracin derivatives contributes to inhibitory activity of Hepatitis B virus to treat liver disorders.
Keywords
Hepatitis B Virus; Talaromyces Species; Molecular Docking;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 T. J. Liang, "Hepatitis B: the virus and disease", Hepatology, Vol. 49, pp. S13-S21, 2009.   DOI
2 N. Gitilin, "HepatitisB: diagnosis, prevention and treatment", Clin. Chem., Vol. 43, pp. 1500-1506, 1997.
3 M. Rizzetto and A. Ciancio, "Chronic HBV-related liver disease", Mol. Aspects Med., Vol. 29, pp. 72-84, 2008.   DOI
4 N. Liu, F. Zhao, H. Jia, D. Rai, P. Zhan, X. Jiang, and X. Liu, "Non-nucleoside anti-HBV agents: advances in structural optimization and mechanism of action investigations", Med. Chem. Commun., Vol. 6, pp. 521-535, 2015.   DOI
5 D. Lavanchy, "Hepatitis B virus epidemiology, disease burden, treatment, current and emerging prevention and control measures", J. Viral Hepatitis, Vol.11, pp. 97-107, 2004.   DOI
6 K. H. Kim, N. D. Kim, and B. L. Seong, "Discovery and development of anti-HBV agents and their resistance", Molecules, Vol. 15, pp. 5878-5908, 2010.   DOI
7 Y. Li, L. Fu, H. Yeo, J. L. Zhu, C. K. Chou, Y. H. Kou, S. F. Yeh, E. Gullen, D. Austin, and Y. C. Cheng, "Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative", Antiviral Chemistry & Chemotherapy, Vol. 16, pp. 193-201, 2005.   DOI
8 E. De Clercq, G. Ferir, S. Kaptein, and J. Neyts, "Antiviral treatment of chronic hepatitis B virus (HBV) infections", Viruses, Vol. 2, pp.1279-1305, 2010.   DOI
9 H. Kwon and A. S. Lok, "Hepatitis B therapy", Nat. Rev. Gastro. Hepat., Vol. 8, pp. 275-284, 2011.   DOI
10 T. M. Block, R. Gish, H. Guo, A. Mehta, A. Cuconati, W. T. London, and J. Guo, "Chronic hepatitis B: what should be the goal for new therapies?", Antivir. Res., Vol. 98, pp. 27-34, 2013.   DOI
11 B. Liu, X. Wen, C. Huang, and Y. Wei, "Unraveling the complexity of hepatitis B virus: From molecular understanding to therapeutic strategy in 50 years", Int. J. Biochem. Cell B., Vol. 45, pp. 1987-1996, 2013.   DOI
12 K. Sato and M. Mori, "Current and novel therapies for Hepatitis B virus infection", Mini-Rev. Med. Chem., Vol. 10, pp. 20-31, 2010.   DOI
13 F. Zoulim and S. Locarnini, "Management of treatment failure in chronic hepatitis B", J. Hepatol., Vol. 56, pp. S112-S122, 2012.
14 A. S. Lok, "Combination Nucleos(t)ide Analogue as Initial Treatment for Chronic Hepatitis B: Have We Put This to Rest?", Hepatology, Vol. 58, pp. 483-485, 2013.   DOI
15 P. R. Daga, J. Duan, and R. J. Doerksen, "Computational model of hepatitis B virus DNA polymerase: Molecular dynamics and docking to understand resistant mutations", Protein Sci., Vol. 19, pp. 796-807, 2010.   DOI
16 S. Locarnini, and W. S. Mason, "Cellular and virological mechanisms of HBV drug resistance", J. Hepatol., Vol. 44, pp. 422-431, 2006.   DOI
17 F. Perveen, R. Qureshi, F. L. Ansari, S. Kalsoom, and S. Ahmed, "Investigations of drug-DNA interactions using molecular docking, cyclic voltammetry and UV-Vis spectroscopy", J. Mol. Struct., Vol. 1004, pp. 67-73, 2011.   DOI
18 C. G. Gadhe, "Comparative modeling of human P-gp NBD2 and docking and binding mode analysis of 8-geranyl chrysin as a P-gp modulator", J. Chosun Natural Sci., Vol. 5, pp. 18-21, 2012.   DOI
19 B. Sathya, "Molecular docking study of naturally-derived neuraminidase inhibitors isolated from phellinus baumii", J. Chosun Natural Sci. Vol. 8, pp. 209-213, 2015.   DOI
20 M. Thirumurthy, "A docking study of newly found natural neuraminidase inhibitor: Erystagallin A", J. Chosun Natural Sci., Vol. 4, pp. 273-277, 2011.
21 SYBYL Software, Tripos Associates Inc, St. Louis, USA, 2006.
22 The PyMOL Molecular Graphics System, Version 1.7.4 Schrodinger, LLC.
23 H. Matsunaga, S. Kamisuki, M. Kaneko, Y. Yamaguchi, T. Takeuchi, K. Watashi, and F. Sugawara, "Isolation and structure of vanitaracin A, a novel anti-hepatitis B viruscompound from Talaromyces sp.", Bioorg. Med. Chem. Lett., Vol. 25, pp. 4325-4328, 2015.   DOI
24 A. N. Jain, "Scoring functions for protein-ligand docking", Curr. Protein Pept. sc., Vol. 7, pp. 407-420, 2006.   DOI
25 A. N. Jain, "Scoring non-covalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities", J. Comput. Aid. Mol. Des., Vol. 10, pp. 427-440, 1996.   DOI